Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/1/2021 | $78.00 | Buy | HC Wainwright & Co. |
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
SC 13G - Greenwich LifeSciences, Inc. (0001799788) (Subject)
10-K - Greenwich LifeSciences, Inc. (0001799788) (Filer)
NT 10-K - Greenwich LifeSciences, Inc. (0001799788) (Filer)
S-8 - Greenwich LifeSciences, Inc. (0001799788) (Filer)
STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following global update on FLAMINGO-01. Flamingo-01 Progress to Date & Future Plans The Company recently confirmed that the preliminary HLA prevalence, safety, and immune response data in FLAMINGO-01 patients is trending as expected in both HLA-A*02 and non-HLA-A*02 arms. The non-HLA-A*02 arm was expanded to 250 patients in 2024 with approval from both EU and US regulators. With t
STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label immune response data. FLAMINGO-01 Immune Response Data Summary The Company has analyzed the preliminary immune response data from FLAMINGO-01. Immune response data in both the HLA-A*02 treated and placebo arms and the third open label arm with all other HLA types (non- HLA-A*02), show that GLSI-100 is creating an immune response over tim
STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to March 31, 2026 which is approximately 66 months from date of the Company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwise modif
HC Wainwright & Co. initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $78.00
Aegis Capital initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $75.00
Aegis Capital initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $75.00
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)